Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas B Johnson

Showing results (11-20 of 375) with videos related to

Pageof 38
Sort By:
Experimental Hematology|May 1, 2012
How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation?Douglas B Johnson, Bipin N Savani
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 28, 2018
Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?Douglas B Johnson, Justin M Balko
American Journal of Clinical Dermatology|September 2, 2017
Combinatorial Therapies in Melanoma: MAPK Inhibitors and BeyondAlice Y Zhou, Douglas B Johnson
JAMA Ophthalmology|June 30, 2018
Continued Poor Survival in Metastatic Uveal Melanoma: Implications for Molecular Prognostication, Surveillance Imaging, Adjuvant Therapy, and Clinical TrialsDouglas B Johnson, Anthony B Daniels
Melanoma Management|September 8, 2018
Advances in the development of intralesional therapies for melanomaDaniel Y Wang, Douglas B Johnson
Drugs|October 1, 2025
Long-Term Toxicities of Immune Checkpoint InhibitorsPreethy E Abraham, Douglas B Johnson
JAMA Oncology|July 17, 2015
Therapeutic Advances and Treatment Options in Metastatic MelanomaDouglas B Johnson, Jeffrey A Sosman
Melanoma Management|September 8, 2018
When to consider alternatives to front-line immune therapies in metastatic melanomaDaniel Y Wang, Douglas B Johnson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2018
Class Matters: Sensitivity of <i>BRAF</i>-Mutant Melanoma to MAPK InhibitionDouglas B Johnson, Kimberly B Dahlman
The Journal of Clinical Endocrinology and Metabolism|December 9, 2022
Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine DysfunctionJordan J Wright, Douglas B Johnson
Pageof 38

Showing results (11-20 of 375) with videos related to

Sort By:
Pageof 38
Experimental Hematology|May 1, 2012
How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation?Douglas B Johnson, Bipin N Savani
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 28, 2018
Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?Douglas B Johnson, Justin M Balko
American Journal of Clinical Dermatology|September 2, 2017
Combinatorial Therapies in Melanoma: MAPK Inhibitors and BeyondAlice Y Zhou, Douglas B Johnson
JAMA Ophthalmology|June 30, 2018
Continued Poor Survival in Metastatic Uveal Melanoma: Implications for Molecular Prognostication, Surveillance Imaging, Adjuvant Therapy, and Clinical TrialsDouglas B Johnson, Anthony B Daniels
Melanoma Management|September 8, 2018
Advances in the development of intralesional therapies for melanomaDaniel Y Wang, Douglas B Johnson
Drugs|October 1, 2025
Long-Term Toxicities of Immune Checkpoint InhibitorsPreethy E Abraham, Douglas B Johnson
JAMA Oncology|July 17, 2015
Therapeutic Advances and Treatment Options in Metastatic MelanomaDouglas B Johnson, Jeffrey A Sosman
Melanoma Management|September 8, 2018
When to consider alternatives to front-line immune therapies in metastatic melanomaDaniel Y Wang, Douglas B Johnson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2018
Class Matters: Sensitivity of <i>BRAF</i>-Mutant Melanoma to MAPK InhibitionDouglas B Johnson, Kimberly B Dahlman
The Journal of Clinical Endocrinology and Metabolism|December 9, 2022
Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine DysfunctionJordan J Wright, Douglas B Johnson
Pageof 38